TCL Archive Clinical Trials: Breast Cancer Prevention Trial requires Fewer Participants, NCI Says September 6, 1996
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Former Group Chair Responds To Niederhuber: Change But Don’t Dissolve Cooperative Groups July 2, 2010
TCL Archive “Evolving Concept” Looks At Appropriate Early Decision Making In Patient Management September 28, 1984
